Patrick Y. Yang, PhD
Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his BS in Engineering from National Chiaotung University (Taiwan), his MS from the University of Cincinnati, and his PhD in Engineering from The Ohio State University.
Sonny Hsiao, PhD
Dr. Hsiao is the Chief Executive Officer, President and Co-Founder at Acepodia. Dr. Hsiao has extensive research experiences in immune celltherapies, which lead to the discovery of components of ACC™(Antibody-Cell Conjugation) technology to the invention of the novelcellular immunotherapy, ACE™ (Antibody-Cell Conjugation Effectorcells). Dr. Hsiao earned his BS in Chemistry from National TaiwanUniversity, and his PhD in Chemistry and Molecular Cell Biology fromthe University of California, Berkeley.
Hong-Jen Chang, MD MPH MS
Dr. Chang is the Chairman and CEO of YFY Biotech Management Company, and CEO of Taiwan Global BioFund. He is also the Chairman of MiCareo Taiwan Company and EUSOL Biotech Company, and Adjunct Professor at National Yang-Ming University. Dr. Chang had been served in 16 years in Taiwan government as Deputy Minister at Department of Health, President & CEO at Bureau of National Health Insurance, and the Director General at Center of Disease Control. Dr. Chang earned his MD from National Yang-Ming Medical College, MPH from National Taiwan University and MS in Health Policy and Management from Harvard University School of Public Health. He was also the visiting scholar at Harvard University School of Public Health.
Jong-Chin Lin, PhD
Mr. Lin is the Chairman of Center Laboratory. Mr. Lin was the former President and Chairman of TTY Biopharm Company and its portfolio companies: Mycenax Biotech, PharmaEngine, Shun Tian Pharmaceutical Biotechnology, TOT Biopharm, TPG Biologics, and TSH Biopharm. Mr. Lin is also the independent board director of Crown Bioscience International, and Partner of TransPacific Medtech Fund. Mr. Lin earned his BA in Pharmacy and the honorary PhD from Taipei Medical University.
Sue Yang, PhD
Dr. Yang had many years of experience in market research, and marketing/business analysis. She worked at General Electric, Merck, Genentech, Roche and Affinita Biotech. Dr. Yang has in-depth knowledge of global pharmaceutical and biotech industry business information, and is an expert in market research, marketing strategy development, and big data analysis. She has a Master’s degree from Ohio University and a PhD degree from the Ohio State University.
Ms. Lee is the president of Asia Pacific Emerging Industry Management Co. Ltd. and CIDC Consultants Inc. with assets over US$ 500M under management. Ms. Lee has more than 25 years of experience in asset management and venture capital, which has invested in more than 500 companies among computer science, internet, semiconductor, telecom and biotech industries. She also has held positions of board member or
supervisor in both private and public portfolio companies to provide
substantial assistance to a business startup. Ms. Lee received her B.A.
in Business Administration from Soochow University and M.S. in
Economics from San Jose State University.